Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report released on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Up 1.9 %

NASDAQ AKTX opened at $3.73 on Monday. The company has a fifty day moving average of $3.01 and a two-hundred day moving average of $2.32. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $5.50.

Institutional Trading of Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC increased its holdings in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 87,628 shares of the biopharmaceutical company’s stock after acquiring an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 as of its most recent SEC filing. 5.06% of the stock is currently owned by institutional investors.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.